RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
6.33
+0.53 (9.14%)
At close: Jan 21, 2025, 4:00 PM
6.30
-0.03 (-0.47%)
After-hours: Jan 21, 2025, 7:37 PM EST
RedHill Biopharma Employees
RedHill Biopharma had 53 employees as of December 31, 2023. The number of employees decreased by 60 or -53.10% compared to the previous year.
Employees
53
Change (1Y)
-60
Growth (1Y)
-53.10%
Revenue / Employee
$69,943
Profits / Employee
-$569,321
Market Cap
8.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RDHL News
- 19 hours ago - RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PRNewsWire
- 6 weeks ago - Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development - PRNewsWire
- 7 weeks ago - RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court - PRNewsWire
- 3 months ago - RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND - PRNewsWire
- 3 months ago - RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury - PRNewsWire
- 3 months ago - RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment - PRNewsWire
- 4 months ago - RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians - PRNewsWire
- 4 months ago - RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 - PRNewsWire